1. Effects of a dual endothelin-1 receptor antagonist on airway obstruction and acute lung injury in sheep following smoke inhalation and burn injury
- Author
-
Katahiro Shimoda, Jiro Katahira, Robert A. Cox, Daniel L. Traber, Lillian D. Traber, Ann S. Burke, Hal K. Hawkins, David N. Herndon, Perenlei Enkhabaatar, and Abhijit Chandra
- Subjects
medicine.medical_specialty ,Endothelin A Receptor Antagonists ,Pyridines ,Smoke Inhalation Injury ,Tetrazoles ,Lung injury ,Nitric Oxide ,Gastroenterology ,Pulmonary function testing ,Tezosentan ,Internal medicine ,medicine ,Animals ,Lung ,Sheep ,business.industry ,Lung Injury ,General Medicine ,respiratory system ,Airway obstruction ,medicine.disease ,Endothelin B Receptor Antagonists ,Oxygen ,medicine.anatomical_structure ,Anesthesia ,Models, Animal ,Female ,Vascular Resistance ,Lymph ,Endothelin receptor ,business ,medicine.drug - Abstract
Studies have suggested that ET-1 (endothelin-1) is associated with lung injury, airway inflammation and increased vascular permeability. In the present study we have tested the hypothesis that treatment with a dual ET-1 receptor antagonist will decrease airway obstruction and improve pulmonary function in sheep with combined S+B (smoke inhalation and burn) injury. Twelve sheep received S+B injury using the following protocol: six sheep were treated with tezosentan, an ETA and ETB receptor antagonist, and six sheep received an equivalent volume of vehicle. Physiological and morphological variables were assessed during the 48 h study period and at the end of the study. There was no statistically significant difference in the PaO2/FiO2 (partial pressure of O2 in arterial blood/fraction of O2 in the inspired gas) ratio of the tezosentan-treated animals compared with controls; however, lung lymph flow was significantly higher (P
- Published
- 2005